FlagInternationalUnited States
 

Overview

Corporate Profile

Uroplasty, Inc. is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices.

Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.

 
Stock Quote
UPI (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$2.63
Change (%) Stock is Down 0.01 (0.38%)
Volume39,940
Data as of 08/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
08/11/14National Government Services Issues Positive Coverage for Percutaneous Tibial Nerve Stimulation
MINNEAPOLIS, Aug. 11, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services (NGS) has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB).  Coverage for the propri... 
 Printer Friendly Version
08/06/14Uroplasty To Participate In Canaccord Genuity 34th Annual Growth Conference
MINNEAPOLIS, Aug. 6, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13.  Rob Kill, President and CEO, will present at 5:00pm ET and meet with investors one on one at the conference at the Intercontinental Hotel Boston. Attendance at th... 
 Printer Friendly Version
07/24/14Uroplasty Reports Fiscal First Quarter Results
~ Urgent PC Sales Up 19% in Fiscal First Quarter ~~Fiscal 2015 Guidance Reaffirmed MINNEAPOLIS, July 24, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 first quarter ended June 30, 2014.  Global revenue for the Company's Urgent® PC Neuromodulation System grew 19% to $4.1 million, as compared to $3.4 mi... 
 Printer Friendly Version
07/10/14Uroplasty To Announce First Quarter Fiscal Year 2015 Financial Results On July 24, 2014
MINNEAPOLIS, July 10, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, will release financial results for the first quarter ended June 30, 2014 after the market close on Thursday, July 24, 2014. The Company will host a conference call and webcast to discuss these results on Thursday, July 24, 2014 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). Ro... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Uroplasty, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.